Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-05 in Alzheimer's Disease Agitation Extension Study
NCT06736509Phase 3Terminated
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Nov 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of dextromethorphan + bupropion in agitation, sponsored by Axsome Therapeutics, Inc. Primary endpoint: Long-Term Safety at 25 weeks. Started Nov 2024; status: terminated.
02
Drugs
dextromethorphan + bupropion
03
Conditions
agitation
Beyond the preview
Go deeper on NCT06736509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736509.